Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 20 Nov 2025
- Expected to end
- 1 Jul 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- MuVI Esophageal mucosal impedance testing
- Record updated
- 27 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with chronic esophageal symptoms such as atypical or typical reflux symptoms and dysphagia, is here for upper endoscopy testing
Who cannot take part
- Presence of esophageal cancer
- Presence of esophageal stricture
- Unstable patients who cannot undergo this testing
- Patients on anticoagulation on the day of procedure
- Pregnancy
- Minor patients
Where in United States
- Froedtert HospitalMilwaukee, United StatesContact: Gokulakrishnan Balasubramanian, MDTaking people
About the trial
What the trial wants to find out
Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making.
Read full original descriptionShow less
Aim:
Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.
The 2 groups in the trial
- True GERD
Positive endoscopy findings or esophageal pH results based on Lyon 2.0
Treatment: MuVI Esophageal mucosal impedance testing
- Functional Heartburn
Negative endoscopy and negative esophageal pH testing results
Treatment: MuVI Esophageal mucosal impedance testing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Diagnostic Utility of Mucosal Impedance Device in Patients With GERD and Chronic Esophageal Disorders:
- Record updated
- 27 July 2026